BriaCell’s Phase 3 Breast Cancer Trial Hits 230-Patient Milestone
Event summary
- BriaCell’s Phase 3 Bria-ABC study has enrolled over 230 patients, with over 315 screened, in its trial of Bria-IMT plus an immune checkpoint inhibitor for metastatic breast cancer.
- Interim topline data is expected in 2026, with the study’s primary endpoint being overall survival (OS).
- The trial has received increased interest from leading cancer centers and was included in Nature Medicine’s list of pivotal trials for 2026.
- Bria-IMT combination regimen continues under FDA Fast Track designation.
The big picture
BriaCell’s rapid enrollment in its Phase 3 trial reflects strong clinical site and patient interest, potentially positioning Bria-IMT as a competitive immunotherapy option in metastatic breast cancer. The FDA Fast Track designation and inclusion in Nature Medicine’s list of key trials underscore the strategic significance of this milestone. Success in this trial could accelerate BriaCell’s path to market, though execution risks remain.
What we're watching
- Regulatory Pathway
- Whether interim OS results will support full approval of Bria-IMT in metastatic breast cancer.
- Trial Momentum
- The pace at which enrollment continues and whether it meets projections for the interim analysis.
- Commercialization Readiness
- How BriaCell advances preparations for potential commercialization while awaiting topline data.
Related topics